Objective：To evaluate the efficacy of fludarabine combined with cyclophosphamide（FC） regimen for chronic lymphocytic leukemia（CLL）. Methods：Clinical data of 41 patients with CLL treated by FC regimen were retrospectively analyzed. Results：The rates of complete response（CR），partial response（PR） and overall response（OR） were 41.5%，36.6% and 78.1% respectively. There was no difference between initial and secondary treatment groups in CR，PR and OR rates（58.8%，23.5%，82.4% vs. 29.1%，45.8%，75%，P ＞0.05）. The main side effects were myelosuppression and immunologic function suppression and there was no difference in hematotoxicity between two groups（P ＞0.05）. The overall sur－vival（OS） and disease-free survival（DFS） rates of 32 patients who had finished 4 cycles of chemotherapy，were 59.1% and 35% respectively.The DFS rate of initial treatment group was better than that of secondary treatment group（53.6% vs. 20.8%，P ＜0.05），but there was no difference in OS rate between two groups（77.1% vs. 47.3%，P ＞0.05）. Conclusions：FC combined chemotherapty regimen can improve the prognosis and disease-free survival of patients with CLL. It is the currently preferred scheme for patients with CLL due to its good efficacy and tolerance，but more attention should be paid to the long-term effect.